New Blood Test May Predict Alzheimer’s Risk, Study Finds

A New Blood Test Could Help Predict Alzheimer’s Risk, but Experts Urge Caution

Researchers say a blood test measuring a protein linked to Alzheimer’s disease could help identify people at increased risk of future cognitive decline. However, experts warn that the test is not intended for routine screening of healthy people and should be interpreted alongside other medical assessments.

A Blood Test Offers New Insights Into Alzheimer’s Risk

Scientists are exploring new ways to identify people who may be at increased risk of developing Alzheimer’s disease before noticeable memory problems begin. A recent study suggests that a blood test measuring a protein known as phosphorylated tau 217, or p-tau217, could provide important information about the likelihood of future cognitive impairment.

The findings indicate that cognitively healthy older adults with higher levels of p-tau217 had an estimated 38% greater risk of developing early signs of dementia within five years than those with lower levels. Over a period of 10 years, the estimated risk was 78% higher, although the researchers noted that the longer-term evidence was less robust.

The results offer further insight into how changes in the brain may be detected before symptoms become obvious. Nevertheless, researchers stress that a higher-risk result does not mean a person will inevitably develop Alzheimer’s disease or dementia.

Rachel Buckley, an associate professor of neurology at Harvard Medical School and the study’s lead author, said the findings support the potential future use of p-tau217 testing to help estimate an individual’s risk of cognitive impairment.

Such information could eventually help doctors identify people who may benefit from closer monitoring, further testing and appropriate preventive care.

Understanding p-tau217 and Its Connection to Alzheimer’s

Alzheimer’s disease is a progressive brain disorder that affects memory, thinking and the ability to carry out everyday activities. It is associated with changes in the brain, including the accumulation of beta-amyloid plaques and abnormal tau proteins.

Beta-amyloid is a protein fragment that can collect between nerve cells, forming plaques that interfere with normal communication in the brain. Tau is another protein that, under abnormal conditions, can form tangled structures inside brain cells.

These changes are associated with damage to neurons and the gradual loss of brain function.

In some people, biological changes linked to Alzheimer’s may begin many years before memory loss or other noticeable symptoms appear. However, the timing and progression of these changes vary considerably from person to person.

The p-tau217 blood test measures a particular form of tau protein associated with Alzheimer’s-related biological processes. Research suggests that its levels can help indicate the likelihood of amyloid accumulation in the brain.

Traditionally, doctors have relied on methods such as brain imaging using positron emission tomography, commonly known as PET scans, and tests involving cerebrospinal fluid collected through a spinal tap to investigate Alzheimer’s-related changes.

Blood tests could provide a less invasive and potentially more accessible way to obtain some of this information.

However, researchers emphasise that a blood test measures only part of a complicated biological process. It cannot independently predict every aspect of a person’s future cognitive health.

Why a Positive Test Does Not Guarantee Dementia

One of the most important points from the research is that elevated levels of Alzheimer’s-related biomarkers do not automatically mean a person will develop dementia.

Some individuals have evidence of amyloid accumulation in the brain but never progress to significant cognitive impairment during their lives. Others may experience different patterns of brain changes depending on their age, genetics, medical history and other health factors.

Buckley explained that the relationship between amyloid and tau may be particularly important. When early tau-related changes occur alongside substantially elevated amyloid levels, the combination may indicate a biological process associated with the spread of Alzheimer’s-related damage.

Nevertheless, this does not make the test a definitive forecast of an individual’s future.

A person’s health is influenced by many interacting factors. These include age, inherited genetic variants, cardiovascular health, other medical conditions and lifestyle.

Consequently, the results must be interpreted carefully, particularly when testing people who do not have memory problems or other symptoms.

Doctors Warn Against Using the Test in Isolation

Although the findings are promising, specialists say p-tau217 testing should not be used as the only method of determining whether someone has Alzheimer’s disease or is likely to develop it.

Dr. Richard Isaacson, a researcher focused on Alzheimer’s prevention and director of research at the Institute for Neurodegenerative Diseases in Florida, emphasised the importance of considering a patient’s broader medical and cognitive profile.

According to Isaacson, a single blood test may provide only a limited view of a complex biological condition. Relying on one result could also increase the possibility of a misleading finding, including a false positive.

A false positive occurs when a test suggests that a condition or biological signal is present even though further investigation does not support that conclusion.

Other health problems may also affect the interpretation of certain biomarkers. For example, kidney dysfunction and some temporary illnesses may complicate the assessment of results.

For these reasons, specialists may combine blood tests with cognitive assessments, medical history, neurological examinations and, when appropriate, additional diagnostic procedures.

The aim is to establish a more complete understanding of a patient’s condition rather than relying on one laboratory measurement.

Experts also caution against interpreting an elevated biomarker level as proof that a person will eventually experience memory loss.

Could Lifestyle Changes Help Reduce Alzheimer’s Risk?

While scientists continue investigating blood-based biomarkers, researchers are also examining how everyday habits and the management of existing medical conditions may influence brain health.

Lifestyle factors frequently discussed in dementia-prevention research include regular physical activity, a balanced diet, adequate sleep, social engagement and activities that challenge the brain.

Managing conditions such as high blood pressure, diabetes and high cholesterol is also important for overall health and may help address some risk factors associated with cognitive decline.

These measures are not guaranteed to prevent Alzheimer’s disease. However, maintaining good cardiovascular and general health can support wellbeing as people grow older.

Researchers are also investigating whether biomarker tests could eventually help doctors monitor changes over time and assess how patients respond to medical treatment or lifestyle interventions.

For example, if future studies establish reliable ways to interpret changes in p-tau217 levels, clinicians may be able to use those measurements alongside other information to understand whether a particular intervention is having a measurable effect.

At present, however, the use of such tests for monitoring prevention strategies remains an area of investigation.

Experts advise people not to treat a blood test as a substitute for medical advice or as a reason to begin unproven treatments. Anyone concerned about memory changes should discuss their symptoms and medical history with a qualified healthcare professional.

What Did the Study Find?

The researchers reanalysed information from six observational and clinical studies conducted in Australia, North America and Japan.

Nearly 2,700 older adults who did not have symptoms of cognitive decline underwent assessments that included p-tau217 blood tests and PET brain scans at the beginning of the studies. Participants were then followed for periods extending up to 21 years.

The researchers found that higher p-tau217 levels were significantly associated with a greater likelihood of developing cognitive impairment.

The association was observed even after accounting for information from brain scans and known genetic risk factors, including the APOE4 variant.

APOE4 is a genetic variant associated with an increased risk of Alzheimer’s disease. Having one copy can increase a person’s risk, while having two copies is associated with a greater increase. However, carrying the variant does not mean that someone will definitely develop the disease.

The researchers said the findings require further investigation, particularly in larger and more diverse populations.

The study’s results are evidence of an association between biomarker levels and future cognitive outcomes. They do not establish that elevated p-tau217 directly causes dementia, nor do they show that every person with a high result will experience cognitive decline.

Further studies will be necessary to determine how accurately the test can estimate risk in different populations and how it should be used in routine medical practice.

How Doctors Are Using Blood Tests in Clinical Care

Separate research presented at an Alzheimer’s Association conference examined how healthcare professionals used p-tau217 testing when assessing patients who already showed signs of dementia or cognitive difficulties.

The study included approximately 1,300 patients and examined how test results influenced diagnostic decisions made by primary care clinicians and specialists.

The findings suggested that test results could influence how doctors approached a diagnosis.

Primary care clinicians changed their diagnosis in around 30% of patients following testing. When results were positive, they were also more likely to refer patients for further specialist assessment rather than immediately making an Alzheimer’s diagnosis.

Dementia specialists changed their diagnoses in approximately 20% of patients. The findings also indicated that specialists were more likely to make an immediate Alzheimer’s diagnosis when the test result was positive.

These differences demonstrate why professional training and clear clinical guidance are important as blood-based Alzheimer’s tests become more widely available.

A test can provide useful evidence, but the meaning of that evidence depends on the patient’s symptoms, medical history and other findings.

Experts say healthcare professionals need additional experience and research-based guidance to determine when these tests should be ordered and how the results should influence treatment decisions.

Why More Research Is Still Needed

Despite the growing interest in blood-based Alzheimer’s testing, researchers say important questions remain unanswered.

The recent findings need to be replicated in larger studies involving people from different backgrounds, with varying health conditions and levels of access to healthcare.

Researchers also need to establish how well the tests perform in everyday clinical settings, where patients may have several medical conditions that complicate diagnosis.

Another important question is whether identifying biological signs of increased risk before symptoms develop will lead to better outcomes for patients.

Early identification could eventually help doctors and patients make informed decisions about monitoring, further assessments and available treatments. However, this potential benefit must be balanced against the possibility of anxiety, unnecessary testing and misunderstanding of results.

For someone who receives a result suggesting an increased risk of Alzheimer’s, it may be difficult to know what that information means without clear medical guidance.

Experts therefore stress that the test should be considered part of a broader assessment rather than a standalone prediction.

The current research does not support recommending p-tau217 testing as a routine screening tool for all cognitively healthy people.

What This Means for the Future of Alzheimer’s Research

Blood-based biomarkers represent an important area of research because they may make some aspects of Alzheimer’s assessment easier and less invasive than traditional approaches.

If further studies confirm their accuracy and establish clear clinical guidelines, these tests could help healthcare professionals investigate suspected Alzheimer’s disease and determine which patients may need additional evaluation.

They could also contribute to research into the biological changes that occur before symptoms become apparent.

However, their usefulness will depend on doctors understanding the limitations of the results and communicating them accurately to patients.

For now, researchers say people should not rush to request a p-tau217 blood test simply because they are concerned about developing dementia.

Instead, anyone experiencing persistent memory problems, confusion or changes in their ability to manage everyday activities should seek medical advice. A healthcare professional can evaluate possible causes and determine whether cognitive testing or further investigations are appropriate.

Memory difficulties can have several causes, and not every instance of forgetfulness is a sign of Alzheimer’s disease.

The emerging research offers encouraging evidence that blood tests may eventually help doctors assess Alzheimer’s-related risk more effectively. But experts agree that more research, careful interpretation and appropriate medical oversight are essential before the tests can be used more broadly.

The key message is clear: a promising blood test may provide valuable information about Alzheimer’s risk, but it is not a diagnosis, and a high-risk result does not mean dementia is inevitable.